LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2-advanced or metastatic breast cancer

被引：0
|
作者：
Hu, Xichun
Wang, Biyun
Wang, Shusen
Tong, Zhongsheng
Sun, Tao
Li, Wei
Song, Lihua
Yan, Xi
Cheng, Ying
Qiu, Fuming
Wang, Xinshuai
Xie, Weimin
Zhao, Bing
Liu, Xinlan
Hu, Changlu
Lai, Guie
Pang, Jinke
Li, Tong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[4] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[5] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[6] First Hosp Jilin Univ, Changchun, Peoples R China
[7] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Jilin Canc Hosp, Changchun, Peoples R China
[10] Zhejiang Univ, Sch Med, Affliated Hosp 2, Hangzhou, Peoples R China
[11] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[12] Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China
[13] Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China
[14] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China
[15] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[16] Jiangxi Med Coll, Affiliated Hosp 1, Ganzhou, Peoples R China
[17] Genor Biopharma Co Ltd, Shanghai, Peoples R China
[18] Genor Biopharma Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S13 - S14
  • [22] Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2-advanced breast cancer enrolled in an early access program
    Brufsky, Adam
    Davis, Keith
    Mitra, Debanjali
    Nagar, Saurabh
    McRoy, Lynn
    Cotter, Matthew
    Stearns, Vered
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S13 - S14
  • [24] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [25] SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ADVANCED OR METASTATIC BREAST CANCER (MBC)
    Riemsma, R.
    Forbes, C. A.
    Amonkar, M.
    Lykopoulos, K.
    Diaz, J. R.
    Kleijnen, J.
    Rea, D. W.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
  • [26] Letrozole plus ribociclib versus letrozole plus placebo as neoadjuvant therapy for ER plus breast cancer (FELINE trial).
    Khan, Qamar J.
    O'Dea, Anne
    Bardia, Aditya
    Kalinsky, Kevin
    Wisinski, Kari Braun
    O'Regan, Ruth
    Yuan, Yuan
    Ma, Cynthia X.
    Jahanzeb, Mohammad
    Trivedi, Meghna S.
    Spring, Laura
    Makhoul, Issam
    Wagner, Jamie L.
    Winblad, Onalisa
    Amin, Amanda Leigh
    Blau, Sibel
    Crane, Gregory James
    Elia, Manana
    Hard, Mia
    Sharma, Priyanka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
    Luis Fein
    Nicolas Lazaretti
    Yamil López Chuken
    J. Rogelio González Ramírez Benfield
    Max S. Mano
    Jose Lobaton
    Ernesto Korbenfeld
    Fernanda Damian
    Dongrui R. Lu
    Ave Mori
    Shem J. Patyna
    Sandra Franco
    Clinical Drug Investigation, 2023, 43 : 699 - 706
  • [28] Phase IIIb CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer (ABC): Interim results from the UK cohort
    Ring, Alistair
    Crook, Timothy
    Tuthill, Mark
    Roylance, Rebecca
    McGoldrick, Trevor
    Chan, Stephen
    Lo'Monte, Helen
    Roberts, William
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).
    De laurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Javier Salvador
    Jacot, William
    Dent, Susan Faye
    Martin, Miguel
    Ring, Alistair E.
    Cottu, Paul H.
    Lu, Janice M.
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    Zamagni, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S15 - S16
12345